Celltech's Flexible Dealmaking
Executive SummaryCelltech's recent research, development and marketing deals with Biogen and Amgen are innovatively flexible, and, combined with a smooth transition in top management at Celltech, may just be the best way to refocus investor attention--distracted by questionable marketing ventures--on the UK company's R&D expertise and late-stage pipeline.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.